Listen as our CEO, Linda Persson, tells about the significant milestone achieved by NanoEcho when we signed the most significant business agreement, so far, with SPL Medical. This ensures the accessibility of the nanoparticles that constitute the contrast agent of our diagnostic method, both for the planned clinical study and for our future sales.
NanoEcho’s innovative method, with its high precision, aims to facilitate the differentiation between diseased and healthy tissue and at the same time determine a more precise localization of cancerous tissue. The goal is to provide a more reliable diagnosis of, for example cancer diseases, that has the potential to contribute to cost-effectiveness in the health care.
Not For Sale – For Clinical Investigation Use Only – EU Trial No.: 2024-515335-29-00